Synbal’s unique advantage is its proprietary technology platform which delivers large DNA cargos (>7 kb) to one chosen DNA site improving safety.  These capabilities allow us to incorporate patient safety elements into our gene edits such as control promoters-operators and kill switches.

 

This groundbreaking technology provides the following advantages:

1. Higher efficiency: it results in increased patient cell transformation rate.
2. Large payload: it allows for a site-directed delivery of large genetic cargos.
3. No virus: it avoids random integration and associated oncology concerns.
4. Kill switch: it allows for unprecedented control of therapeutic strength.

 

Synbal’s technology originated in the laboratories of Dr. Ethan Bier and Valentino Gantz of UCSD. The unique benefits of their technology innovation recruits Homology-Directed Repair (HDR) coupled with CRISPR/Cas9 (or other nucleases), a site-specific gRNA, and other proprietary technologies making HDR much more efficient in somatic cells.

Synbal’s Active Genetics Technology Applied to Laboratory Animals and Cell-Based Therapuetics

Download Synbal’s Executive Summary >>

 

Synbal’s Progress:

• September 2018: Synbal was awarded a Small Business Innovation Research (SBIR) Fast Track award for $2.3M to develop a humanized rat model. This rat will express 9 different human Cytochrome P450 genes responsible for metabolizing 80% of commercial small molecule drugs. If successful, this will provide an invaluable resource for studying human drug metabolism in rat models for drug pharmacokinetics validation of study of human diseases.
• October 2018: Synbal opened its laboratories in the BioLabs facility in San Diego, CA. Currently there are two scientific staff at the PhD level along with the CSO and the CEO.
• October 2018: A second contract ($2.6M) has also been awarded to Synbal by a Biopharmaceutical company to develop a humanized, multigene animal model in the mouse.  The funds from both sources are exclusively for the development of laboratory animal models and provide the company with sufficient operating funds for approximately three years.